PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:PBH - US74112D1019 - Common Stock
65.12 USD
-0.49 (-0.75%)
65.12 USD
0 (0%)
Taking everything into account, PBH scores 6 out of 10 in our fundamental rating. PBH was compared to 190 industry peers in the Pharmaceuticals industry. PBH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. PBH is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- PBH had positive earnings in the past year.
- In the past year PBH had a positive cash flow from operations.
- Of the past 5 years PBH 4 years were profitable.
- PBH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- With an excellent Return On Assets value of 5.83%, PBH belongs to the best of the industry, outperforming 86.84% of the companies in the same industry.
- The Return On Equity of PBH (11.00%) is better than 85.79% of its industry peers.
- PBH's Return On Invested Capital of 7.88% is amongst the best of the industry. PBH outperforms 85.79% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for PBH is below the industry average of 12.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROIC | 7.88% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
- PBH has a Profit Margin of 18.09%. This is amongst the best in the industry. PBH outperforms 90.00% of its industry peers.
- In the last couple of years the Profit Margin of PBH has grown nicely.
- The Operating Margin of PBH (31.00%) is better than 94.21% of its industry peers.
- PBH's Operating Margin has been stable in the last couple of years.
- PBH's Gross Margin of 56.10% is fine compared to the rest of the industry. PBH outperforms 67.89% of its industry peers.
- In the last couple of years the Gross Margin of PBH has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PBH is destroying value.
- PBH has less shares outstanding than it did 1 year ago.
- Compared to 5 years ago, PBH has less shares outstanding
- The debt/assets ratio for PBH has been reduced compared to a year ago.
2.2 Solvency
- PBH has an Altman-Z score of 2.62. This is not the best score and indicates that PBH is in the grey zone with still only limited risk for bankruptcy at the moment.
- PBH has a better Altman-Z score (2.62) than 64.21% of its industry peers.
- PBH has a debt to FCF ratio of 3.97. This is a good value and a sign of high solvency as PBH would need 3.97 years to pay back of all of its debts.
- PBH has a better Debt to FCF ratio (3.97) than 86.32% of its industry peers.
- A Debt/Equity ratio of 0.55 indicates that PBH is somewhat dependend on debt financing.
- PBH has a worse Debt to Equity ratio (0.55) than 66.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Altman-Z | 2.62 |
ROIC/WACC0.89
WACC8.89%
2.3 Liquidity
- PBH has a Current Ratio of 3.70. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
- PBH has a Current ratio (3.70) which is comparable to the rest of the industry.
- PBH has a Quick Ratio of 2.51. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
- PBH has a Quick ratio (2.51) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 13.15% over the past year.
- The Earnings Per Share has been growing by 8.88% on average over the past years. This is quite good.
- Looking at the last year, PBH shows a decrease in Revenue. The Revenue has decreased by -0.02% in the last year.
- Measured over the past years, PBH shows a small growth in Revenue. The Revenue has been growing by 3.39% on average per year.
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
3.2 Future
- PBH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.13% yearly.
- Based on estimates for the next years, PBH will show a small growth in Revenue. The Revenue will grow by 1.15% on average per year.
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 14.28, the valuation of PBH can be described as correct.
- Based on the Price/Earnings ratio, PBH is valued cheaper than 87.37% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.47. PBH is valued slightly cheaper when compared to this.
- The Price/Forward Earnings ratio is 13.30, which indicates a correct valuation of PBH.
- Based on the Price/Forward Earnings ratio, PBH is valued cheaply inside the industry as 83.68% of the companies are valued more expensively.
- The average S&P500 Price/Forward Earnings ratio is at 24.26. PBH is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.28 | ||
| Fwd PE | 13.3 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PBH indicates a rather cheap valuation: PBH is cheaper than 86.84% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, PBH is valued cheaper than 88.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.26 | ||
| EV/EBITDA | 10.84 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
- PBH has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)8.7
PEG (5Y)1.61
EPS Next 2Y3.96%
EPS Next 3Y3.41%
5. Dividend
5.1 Amount
- PBH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
65.12
-0.49 (-0.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-05 2026-02-05/bmo
Inst Owners108.83%
Inst Owner Change1.62%
Ins Owners1.31%
Ins Owner Change0.82%
Market Cap3.13B
Revenue(TTM)1.11B
Net Income(TTM)200.84M
Analysts84
Price Target79.05 (21.39%)
Short Float %4.5%
Short Ratio4.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.61%
Min EPS beat(2)-5.96%
Max EPS beat(2)9.18%
EPS beat(4)3
Avg EPS beat(4)2.04%
Min EPS beat(4)-5.96%
Max EPS beat(4)9.18%
EPS beat(8)5
Avg EPS beat(8)-0.36%
EPS beat(12)7
Avg EPS beat(12)-46.48%
EPS beat(16)11
Avg EPS beat(16)-33.78%
Revenue beat(2)1
Avg Revenue beat(2)0.1%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)5.55%
Revenue beat(4)3
Avg Revenue beat(4)0.5%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)5.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)5
Avg Revenue beat(12)-0.15%
Revenue beat(16)9
Avg Revenue beat(16)0.5%
PT rev (1m)0%
PT rev (3m)-7.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.36%
EPS NY rev (1m)0%
EPS NY rev (3m)0.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.13%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.28 | ||
| Fwd PE | 13.3 | ||
| P/S | 2.82 | ||
| P/FCF | 12.26 | ||
| P/OCF | 11.89 | ||
| P/B | 1.72 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.84 |
EPS(TTM)4.56
EY7%
EPS(NY)4.9
Fwd EY7.52%
FCF(TTM)5.31
FCFY8.16%
OCF(TTM)5.48
OCFY8.41%
SpS23.1
BVpS37.96
TBVpS-20.68
PEG (NY)8.7
PEG (5Y)1.61
Graham Number62.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROCE | 10.41% | ||
| ROIC | 7.88% | ||
| ROICexc | 8.17% | ||
| ROICexgc | 70.59% | ||
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% | ||
| FCFM | 23% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score7
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 27.11% | ||
| Cap/Sales | 0.72% | ||
| Interest Coverage | 7.8 | ||
| Cash Conversion | 70.49% | ||
| Profit Quality | 127.19% | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 | ||
| Altman-Z | 2.62 |
F-Score7
WACC8.89%
ROIC/WACC0.89
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
EBIT growth 1Y5.81%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year6.22%
EBIT Next 3Y3.43%
EBIT Next 5Y3.05%
FCF growth 1Y18.43%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y17.36%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%
PRESTIGE CONSUMER HEALTHCARE / PBH FAQ
What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PBH.
Can you provide the valuation status for PRESTIGE CONSUMER HEALTHCARE?
ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.
What is the profitability of PBH stock?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.
What is the expected EPS growth for PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 1.64% in the next year.